Updates are available Correction dated 2020-10-22
Click to view Correction: https://doi.org/10.1007/s00213-020-05682-x
-
Authors
Yanakieva, Steliana
Polychroni, Naya
Family, Neiloufar
Williams, Luke T. J.
Luke, David P.
Terhune, Devin B. http://orcid.org/0000-0002-6792-4975
-
Funding
Funding for this research was provided by:
Eleusis Benefit Corporation
H2020 Marie Skłodowska-Curie Actions
- License Information
-
More Information
Article History
Received: 23 May 2018
Accepted: 9 November 2018
First Online: 26 November 2018
Change Date: 22 October 2020
Change Type: Correction
Change Details: The manufacturer of the drug product was Onyx Scientific Limited UK, to cGMP standards.
Compliance with ethical standards
: The study was conducted in compliance with the study protocol and the ethical principles of the Declaration of Helsinki. The study protocol and informed consent form were approved by the Independent Ethics Committee for the Early Phase unit in accordance with the International Conference on Harmonisation, Good Clinical Practice, and the UK law.
: SY, NF, LTJW, DPL, and DBT were paid consultants of Eleusis Benefit Corporation (USA) at the time of the clinical trial.
